Algert Global LLC Boosts Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

Algert Global LLC raised its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 34.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,164 shares of the company’s stock after buying an additional 5,910 shares during the period. Algert Global LLC’s holdings in Vera Therapeutics were worth $1,024,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after purchasing an additional 350 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Vera Therapeutics by 14.4% during the 2nd quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock worth $358,000 after purchasing an additional 1,250 shares during the last quarter. Ensign Peak Advisors Inc increased its stake in shares of Vera Therapeutics by 13.5% during the 2nd quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock worth $425,000 after purchasing an additional 1,400 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Vera Therapeutics by 30.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock worth $272,000 after purchasing an additional 1,737 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its stake in shares of Vera Therapeutics by 19.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the company’s stock worth $610,000 after purchasing an additional 2,200 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Up 2.9 %

Shares of NASDAQ:VERA opened at $48.83 on Friday. The firm has a fifty day moving average price of $43.94 and a two-hundred day moving average price of $39.65. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a one year low of $12.58 and a one year high of $51.61. The company has a market cap of $3.09 billion, a price-to-earnings ratio of -18.71 and a beta of 1.03.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VERA has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Scotiabank assumed coverage on shares of Vera Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price objective for the company. Wedbush lifted their price objective on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Finally, Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Vera Therapeutics currently has an average rating of “Buy” and a consensus target price of $59.22.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the completion of the sale, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $14,182,110.60. The trade was a 6.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Beth C. Seidenberg sold 15,000 shares of Vera Therapeutics stock in a transaction on Monday, October 28th. The stock was sold at an average price of $48.03, for a total transaction of $720,450.00. Following the sale, the director now directly owns 131,553 shares of the company’s stock, valued at $6,318,490.59. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,927 shares of company stock valued at $3,800,796. Insiders own 21.70% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.